ストックスクリーナーアプリを入手
17.71
0.17%
-0.02
前日終値:
$17.73
開ける：
$17.87
24時間の取引高:
84,127
Relative Volume:
0.10
時価総額：
$1.99B
収益：
$454.68M
当期純損益:
$-178.68M
株価収益率:
-10.93
EPS:
-1.6209
ネットキャッシュフロー:
$-135.66M
1週間 パフォーマンス:
+6.31%
1か月 パフォーマンス:
-14.04%
6か月 パフォーマンス:
+4.12%
1年 パフォーマンス:
-56.44%
1日の値動き範囲:
$17.62
$17.96
1週間の範囲:
$16.76
$18.06
52週間の値動き範囲:
$15.96
$41.20
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Compare ZLAB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
17.73 | 1.99B | 454.68M | -178.68M | -135.66M | -1.6209 |
VRTX
Vertex Pharmaceuticals Inc
|
449.73 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.46 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.90 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.34 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.46 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-14 | 開始されました | Morgan Stanley | Overweight |
| 2023-08-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-01-21 | 開始されました | Macquarie | Outperform |
| 2021-10-12 | 開始されました | Bernstein | Mkt Perform |
| 2020-04-28 | 開始されました | Goldman | Buy |
| 2020-04-15 | 開始されました | Guggenheim | Buy |
| 2019-07-12 | 開始されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
| 2019-01-29 | 開始されました | Credit Suisse | Outperform |
| 2018-11-21 | 開始されました | Jefferies | Buy |
| 2018-06-21 | 再開されました | Leerink Partners | Outperform |
| 2018-02-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 開始されました | JP Morgan | Neutral |
| 2017-10-16 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Zai Lab Limited Adr (ZLAB) 最新ニュース
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas - Business Wire
Number of shareholders of Zai Lab Ltd. Sponsored ADR – SWB:1ZL - TradingView
TCG Crossover funds, Chen Yu hold 5.3% of ZLAB (ADS positions) - Stock Titan
China’s TIVDAK Approval in Advanced Cervical Cancer Could Be A Game Changer For Zai Lab (ZLAB) - Sahm
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - BioSpace
Trial's China arm: TIVDAK cuts death risk 45% vs chemo in cervical cancer - Stock Titan
(tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer - Business Wire
Equity grants for Zai Lab (ZLAB) operating partner Wang Yizhe - Stock Titan
Zai Lab (ZLAB) Operating Partner Wang Yizhe listed as insider on Form 3 - Stock Titan
Zai Lab Ltd (ADR) stock (CA98959U1084): Oncology pipeline and US listing in focus - AD HOC NEWS
UnitedHealth, Regeneron Pharmaceuticals and other big stocks moving lower in Monday's pre-market session - MSN
Zai Lab (NASDAQ: ZLAB) CEO gifts 107,700 ADS to adult son’s trusts - Stock Titan
Zai Lab Announces Changes to Senior Leadership Team - Business Wire
Zai Lab Ltd stock (US98887Q1040): analyst downgrade adds pressure after biotech news flow - AD HOC NEWS
Zai Lab Ltd stock (KYG9887Y1016): recent earnings and oncology pipeline in focus - AD HOC NEWS
Zai Lab (NASDAQ: ZLAB) president and COO departs; CEO assumes duties - Stock Titan
Zai Lab (ZLAB) CEO sells 100,000 ADS in Rule 10b5-1 trades - Stock Titan
UnitedHealth, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
CICC Cuts ZAI LAB (09688.HK) TP to HKD20.2; 1Q Results In Line - AASTOCKS.com
Ying Du files Form 144 to sell ADS blocks (ZLAB) - Stock Titan
Zai Lab (ZLAB) CLO sells 3,517 ADS under Rule 10b5-1 plan - Stock Titan
Zai Lab (ZLAB) CEO exercises 100K options and sells 100K ADSs under plan - Stock Titan
ZLAB (NASDAQ: ZLAB) insider files multiple ADS sale notices totaling repeated 50,000‑share lines - Stock Titan
BOCI Downgrades ZAI LAB (09688.HK) to Hold, Halves TP to HKD17 - AASTOCKS.com
Ying Du sells multiple American Depositary Shares (ZLAB) across March–May 2026 - Stock Titan
KE Holdings Inc American Depositary Shares (each representing three Class A (NY: BEKE - FinancialContent
ZLAB (NASDAQ) insider reports ADS sales totaling multiple tranches in March–April 2026 - Stock Titan
50,000 ADS sale notice for ZLAB (NASDAQ: ZLAB) on 05/13/2026 - Stock Titan
M Stanley Cuts ZAI LAB (09688.HK) TP to HKD19, Reflecting Post-1Q Results Forecast Revisions - AASTOCKS.com
Zai Lab Limited (NASDAQ:ZLAB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs) - ChartMill
Zai Lab Q1 Earnings Call Highlights - Yahoo Finance
ZAI LAB (09688.HK) 1Q Net Loss Widens to USD51.02 million - AASTOCKS.com
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Zai Lab (NASDAQ: ZLAB) Q1 revenue dips 6% as ZEJULA weakens - Stock Titan
Zai Lab (NASDAQ: ZLAB) Q1 2026 revenue slips as R&D and ADC pipeline advance - Stock Titan
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates - ChartMill
Which Is a Better Investment, AnaptysBio, Inc. or Zai Lab Limited Stock? - AAII.com
Zai Lab (ZLAB) Expected to Announce Earnings on Thursday - MarketBeat
Zai Lab (NASDAQ: ZLAB, HKEX: 9688) details 2026 AGM votes on board, pay, 10% mandates - Stock Titan
BofAS Raises Zai Lab (09688.HK) TP to HKD18.6, Rating Neutral - AASTOCKS.com
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor Call - Yahoo Finance
Assessing Zai Lab (NasdaqGM:ZLAB) Valuation After Recent Share Price Momentum Shift - Sahm
Zai Lab (NASDAQ:ZLAB) Trading Down 5.2%Here's What Happened - MarketBeat
How many employees work at Zai Lab? - Revelio Labs
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 - BioSpace
Zai Lab Ltd (ADR) stock (CA98959U1084): Why Google Discover changes matter more now - AD HOC NEWS
Zai Lab Ltd stock (US98887Q1040): Is its China oncology focus strong enough to unlock new upside? - AD HOC NEWS
Zai Lab and Amgen Launch Clinical Trial for Lung Cancer Therapy - HarianBasis.co
Zai Lab (ZLAB), Amgen (AMGN) Partner to Evaluate Combination Lung Cancer Therapy - Yahoo Finance
Zai Lab Limited Adr (ZLAB) 財務データ
収益
当期純利益
現金流量
EPS
Zai Lab Limited Adr (ZLAB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Du Ying | Chairperson & CEO |
May 15 '26 |
Option Exercise |
1.74 |
50,000 |
87,000 |
1,172,626 |
| Du Ying | Chairperson & CEO |
May 18 '26 |
Option Exercise |
1.74 |
50,000 |
87,000 |
1,172,626 |
| Du Ying | Chairperson & CEO |
May 15 '26 |
Sale |
20.74 |
50,000 |
1,037,110 |
1,122,626 |
| Du Ying | Chairperson & CEO |
May 18 '26 |
Sale |
19.00 |
50,000 |
949,765 |
1,122,626 |
1.61%
大文字化:
|
ボリューム (24 時間):